CSL and uniQure unveil three-year data for one-time hemophilia B gene therapy that costs $3.5M
With its $3.5 million price tag, CSL Behring and uniQure’s one-off hemophilia B gene therapy Hemgenix is one of the world’s most expensive therapies. On …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
